Jill Feldman, Lung Cancer Patient and Advocate, Co-Founder of EGFR Resisters, shared Misty Dawn Shields, Assistant professor of clinical medicine at Indiana University, post on X, adding:
“I appreciate you Misty Dawn Shields! As data from trials like ADAURA mature, we need to have these conversations.
The survival benefit is incredible. Now we need to understand who needs treatment, who may not, who is still under the curve, and how we better support the real-life burdens of cancer and treatment.
We must celebrate progress, but progress should also push us to be more precise.”
Quoting Misty Dawn Shields’s post:
“Fierce patient advocate and lung cancer survivor Jill Feldman asking key questions on the implementation of ADAURA at WCLC26”
____ ____ ____
Jill Feldman and Misty Dawn Shields were recognized among OncoDaily’s ‘100 Influential Cancer Survivors on Social Media: 2026 Edition’ and ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025’ respectfully, highlighting their contributions to the field of oncology.
Nominations for ‘100 Influential People in Oncology 2026’ are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit Your Nomination by September 15.
